Skip to main content
SUMOylation as a therapeutic target in inflammatory bowel diseases and sepsis

SUMOylation as a therapeutic target in inflammatory bowel diseases and sepsis

Unmet Need Inflammatory Bowel Disease (IBD) affects between 2.4 – 3.1 million people in the USA alone, with significant risks of complications such as sepsis. Chronic inflammation from IBD results in severe intestinal tissue damage,…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us